Eosinophilic esophagitis (EoE) is an immune-mediated clinicopathological condition characterized by symptoms of esophageal dysfunction in the setting of eosinophilic infl ammation on esophageal biopsy ( 1,2 ). Over the past decade, this condition has become increasingly recognized, and it is now frequently encountered in patients undergoing upper endoscopy ( 3 -5 ). However, the fi nding of esophageal eosinophilia is not specifi c for EoE. Th e diff erential diagnosis is relatively broad and can include infections, drug hypersensitivity, autoimmune and Proton-pump inhibitor-responsive esophageal eosinophilia (PPI-REE) is a newly recognized entity that must be differentiated from eosinophilic esophagitis (EoE). Little is known about this condition. We aimed to determine the prevalence of PPI-REE and EoE in patients undergoing upper endoscopy and determine features that distinguish the two groups.
INTRODUCTION
connective tissue disorders, and hypereosinophilic syndrome ( 1, 2, 6, 7 ) . From a practical standpoint, however, gastroesophageal refl ux disease (GERD) and proton-pump inhibitor-responsive esophageal eosinophilia (PPI-REE) are the most commonly encountered conditions that must be distinguished from EoE ( 1, 2, 8 ) .
In particular, the recent recognition of PPI-REE has complicated the diagnostic algorithm for EoE. PPI-REE is the term used to describe patients with esophageal eosinophilia on biopsy who respond to a course of PPI therapy. It was fi rst observed in a series of pediatric patients ( 9 ) , and now accounts for at least one-third of children and adults with esophageal eosinophilia ( 10 -15 ) . Although recent guidelines require the exclusion of PPI-REE with a PPI trial before a formal diagnosis of EoE can be made ( 1, 2 ) , it is currently unclear if PPI-REE is a subtype of GERD, an EoE phenotype, or an independent condition. In addition, the prevalence of PPI-REE has not been prospectively determined in a cohort in the United States. PPI-REE is poorly understood, and predictors that might distinguish EoE from PPI-REE are unknown.
Th e aim of this study was to determine the prevalence of PPI-REE and EoE in patients with and without dysphagia undergoing upper endoscopy and to determine whether clinical, endoscopic, or histological features could distinguish the two groups. Based on our experience, we hypothesized that no such factors would distinguish PPI-REE from those with EoE.
METHODS

Study design and patients
Th is was a prospective cohort study conducted at the University of North Carolina (UNC) between 2009 and 2011. Consecutive adult patients (aged 18 -80 years) referred for routine outpatient esophagogastroduodenoscopy were recruited from the two UNC gastrointestinal (GI) procedure units. Patients were stratifi ed by indication (dysphagia vs. other indications) and enrolled in an approximately 3:1 ratio of dysphagia vs. non-dysphagia indications, in order to enrich the study pool for patients with dysphagia. Subjects were excluded if they had a known (prevalent) diagnosis of EoE or a diff erent eosinophilic gastrointestinal disorder, GI bleeding, active anticoagulation, known esophageal cancer, previous esophageal surgery, known esophageal varices, medical instability or multiple comorbidities precluding enrollment in the clinical opinion of the endoscopist, or inability to read or understand the consent form. Subjects provided informed consent and were enrolled before the endoscopy. Th is study was approved by the UNC Institutional Review Board.
Subjects with a new (incident) diagnosis of EoE met consensus guidelines ( 1 ) . Specifi cally, cases were required to have at least one typical symptom of esophageal dysfunction (e.g., dysphagia, food impaction, heartburn, or feeding intolerance); at least 15 eosinophils per high-power fi eld (eos / hpf) on esophageal biopsy persisting aft er an 8-week PPI trial (20 -40 mg twice daily of any of the available agents, prescribed at the discretion of the clinician); and other causes of esophageal eosinophilia excluded. Although the majority of the EoE group included subjects who were PPI-naive on their index endoscopy ( n = 24), there were patients who were on high-dose PPI for at least 8 weeks at the time of their index endoscopy ( n = 17) who did not have pre-PPI endoscopy or histology data available.
Subjects with PPI-REE were required to have at least one typical symptom of esophageal dysfunction (e.g., dysphagia, food impaction, heartburn, or feeding intolerance); at least 15 eos / hpf on esophageal biopsy; improvement of esophageal eosinophilia to < 15 eos / hpf aft er an 8-week PPI trial (20 -40 mg twice daily of any of the available agents, prescribed at the discretion of the patient ' s clinician); and improvement of symptoms by self-report at the time of the repeat endoscopy. By defi nition, the PPI-REE group included only subjects who were PPI-naive at the time of their index endoscopy and required follow-up endoscopy aft er the PPI trial.
Clinical and histological data
Clinical data including demographics, symptoms, and the indications for endoscopy were recorded. At the time of enrollment, a blood sample was drawn for the peripheral eosinophil count (cells × 10 9 / l) and total immunoglobulin E (IgE) level (kU / l). During endoscopy, all endoscopic fi ndings were recorded using a standardized case report form. A total of fi ve research protocol esophageal biopsies were obtained (two from the proximal, one from the mid, and two from the distal esophagus) to maximize the sensitivity of EoE diagnosis ( 16 ) . Additional clinical biopsies were taken as needed at the discretion of the endoscopist. Esophageal biopsies were reviewed by the study pathologists to determine eosinophil counts according to our previously validated protocol ( 17 ) . In brief, the slides were masked to the clinical case status and digitized. Using Aperio ImageScope (Aperio Technologies, Vista, CA), the maximum eosinophil density (eosinophils / mm 2 ( eos / mm 2 )) was determined aft er examination of fi ve microscopic fi elds from each of the fi ve biopsies. For purposes of comparison with previous studies, eosinophil density was then converted to eosinophil counts (eos / hpf) for an assumed hpf size of 0.24 mm 2 , the size of an average fi eld as reported in the literature ( 18 ) . Th e eosinophil infi ltration was further examined to determine whether it was patchy (localized eosinophilia ≥ 15 eos / hpf in only one hpf in the biopsy) or diffuse (eosinophilic infl ammation seen in multiple hpfs) throughout the entire biopsy sample, as well as whether the eosinophil distribution throughout the mucosa was superfi cial only, basal only, or diff use (throughout the epithelium). Notably, gastric and duodenal biopsies were also collected and examined to exclude co-existing eosinophilic gastritis or gastroenteritis.
Statistical analysis
Characteristics of the study groups were summarized using descriptive statistics, and the proportion of EoE cases and PPI-REE subjects were calculated. Bivariate comparisons were made between patients with and without esophageal eosinophilia ≥ 15 eos / hpf and between EoE cases and PPI-REE subjects. Chisquare was used for categorical variables and t -tests were used for continuous variables. For the comparison between EoE and PPI-REE, baseline data from the PPI-naive visit were used. Th us, patients diagnosed with EoE on an index endoscopy while on high-dose PPI were excluded from these comparisons. Multivariable logistic regression was used to assess for factors that would independently distinguish PPI-REE and EoE. Based on the fi nal sample size, diff erent models were constructed with no more than four covariates.
RESULTS
Patient fl ow and characteristics of subjects with esophageal eosinophilia
Th ere were 565 patients screened for this study ( Figure 1 ). Of these, 205 were ineligible (26 were out of the age range, 22 had GI bleeding, 6 had esophageal cancer, 6 had previous esophageal resection, 9 had esophageal varices, 2 were actively anticoagulated, 26 had previous EoE or eosinophilic gastrointestinal disorder, 89 had medical instability / comorbidities, 19 did not speak English and were unable to provide consent), 48 were screened but cancelled their endoscopy appointment, 36 were screened but were unable to be recruited at the time of endoscopy, and 53 refused participation.
Of the 223 subjects who were enrolled, 173 had dysphagia while 50 did not. Of the 173 patients with dysphagia, 66 (38 % ) had esophageal eosinophilia with ≥ 15 eos / hpf. Aft er the PPI-trial, 40 (23 % ) were confi rmed to have EoE, 24 (14 % ) had PPI-REE, and 1 (0.6 % ) had eosinophilic gastroenteritis. Of the 50 patients without dysphagia, 2 (4 % ) had esophageal eosinophilia with ≥ 15 eos / hpf. Aft er the PPI trial, 1 (2 % ) had EoE and 1 (2 % ) had eosinophilic gastroenteritis.
Th ere were multiple clinical, endoscopic, and histological differences between those with and without esophageal eosinophilia ( Table 1 ) . When compared with subjects without esophageal eosinophilia, those with eosinophil counts ≥ 15 eos / hpf were younger (41 vs. 54 years; P < 0.001), more likely to be male (73 vs. 37 % ; P < 0.001), and more likely to be white (92 vs. 77 % ; P = 0.006). Th ey were less likely to have a normal endoscopic exam (2 vs. 23 % ; P < 0.001) and more likely to have the typical fi ndings of EoE, including esophageal rings, strictures, narrowing, linear furrows, crepe-paper mucosa, and decreased vascularity.
When examining the post-PPI treatment eosinophil counts, there were several histologically borderline cases. In the EoE . For the esophageal eosinophil group, this value is the baseline count for the 48 subjects who had a PPI-naive baseline endoscopy.
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Prevalence of PPI-REE and EoE group, there were three subjects with an eosinophil count of 16; all of the other subjects had counts > 20 eos / hpf. In the PPI-REE group, there were four patients with an eosinophil count of 14 eos / hpf and four patients with an eosinophil count of 13 eos / hpf; the remainder of the subjects had counts < 10 eos / hpf. In this group, however, these counts were substantially decreased from a mean of 90 aft er the PPI therapy (the pre-PPI individual counts were 256, 100, 40, 120, 25, 53, 57, and 49 eos / hpf).
EoE cases and PPI-REE subjects
When the 24 PPI-REE subjects and 41 EoE cases were compared, those with PPI-REE were more likely to be older (48 vs. 36 years; P < 0.001), male (88 vs. 63 % ; P = 0.04), and have a Schatzki ' s ring (21 vs. 4 % ; P = 0.01) ( Table 2 ). Th ey were less likely to have esophageal rings (63 vs. 100 % ), narrowing (8 vs. 33 % ; P = 0.03), linear furrows (58 vs. 92 % ; P = 0.008), and decreased vascularity (0 vs. 17 % ; P = 0.04). Th ere was no diff erence in the maximum pre-PPI-trial eosinophil count between the PPI-REE and EoE groups (58 vs. 63 eos / hpf; P = 0.74). There were also no significant differences in eosinophil distributions. The eosinophil infiltration was patchy throughout the biopsy specimen in 61 % of the EoE subjects as compared with 83 % of those with PPI-REE ( P = 0.16). In the EoE group, the eosinophil mucosal distribution was superficial, basal, and diffuse, in 7, 24, and 69 % , respectively, and in the PPI-REE group it was 27, 9, and 63 % , respectively ( P = 0.17). Although the peri pheral blood eosinophil count was statistically lower in the PPI-REE group, levels for both the groups were still within the normal range (0.21 vs. 0.35 cells × 10 9 / l; P = 0.01); there were no differences for the total IgE level. After the PPI-trial, the mean eosinophil count was 9 eos / hpf in the PPI-REE group (range 0 -14 eos / hpf; interquartile range 4 -13 eos / hpf).
On multivariate analysis, there were no independent clinical, endoscopic, or histological predictors that reliably distinguished PPI-REE from EoE.
DISCUSSION
With the increasing recognition and diagnosis of EoE, esophageal eosinophilia is being encountered more frequently ( 2 ) . Although the most common causes of esophageal eosinophilia were presumed to be GERD and EoE ( 7 ), the recent identifi cation of PPI-REE has complicated the diagnostic algorithms, and this condition is little understood ( 1,2,9,12 ) . Th e present study aimed to determine the prevalence of EoE and PPI-REE in patients undergoing endoscopy and assess whether clinical, endoscopic, or histological features could distinguish the two groups. Th ere are several key fi ndings. First, esophageal eosinophilia is commonly encountered in the GI procedure unit, with nearly 40 % of subjects with dysphagia and 4 % of patients without dysphagia having ≥ 15 eos / hpf, the current threshold required to suspect a diagnosis of EoE. Second, aft er an 8-week PPI trial, almost one quarter of patients with dysphagia and 2 % of those without dysphagia were confi rmed to have EoE by consensus guidelines. However, more than one-third of patients with esophageal eosinophilia were found to have PPI-REE. Th ird, no clinical, endoscopic, or histological feature independently distinguished EoE from PPI-REE before the PPI trial.
Several previous studies have assessed the prevalence of EoE in patients undergoing endoscopy. Th e rate has ranged from 6.5 % in all patients undergoing endoscopy ( 4 ) to 12 -15 % in patients undergoing endoscopy with an indication of dysphagia ( 3, 5 ) and to more than 50 % in patients undergoing an endoscopy in eosinophilia, where the rates of PPI response were remarkably similar at 33 and 35 % ( 22,23 ). Th ere are several mechanisms that might explain this response to PPI medications. It is possible that in some patients with PPI-REE, the esophageal eosinophilic infi ltrate is due to GERD, and the mechanism is simply related to decreasing acid exposure ( 27, 28 ) . Similarly, it is possible that PPIs heal damaged epithelial barriers in EoE, thus decreasing antigen exposure and reducing eosinophilia ( 27 ) . It is also possible that PPIs have a direct anti-eosinophilic / anti-infl ammatory eff ect ( 29, 30 ) . Others suggest that PPIs may decrease eosinophil degranulation ( 31 ) .
Regardless of the mechanism, it is diffi cult to predict which patients with esophageal eosinophilia will respond to PPIs and which will have EoE. In our study, while those with PPI-REE were somewhat older and had fewer typical endoscopic fi ndings of EoE, the groups were largely indistinguishable, and clinical, endoscopic, and histological factors were not predictive aft er multivariate analysis. Th ese fi ndings are similar to those of other investigators ( 12, 32 ) as well as recent abstract data showing that eotaxin-3 and T helper type 2 cytokines were decreased in PPI-REE patients, in patterns similar to what is observed aft er EoE patients are treated with topical steroids ( 33 ) . Currently, it remains unknown if some patients with PPI-REE will eventually be categorized as a subtype of EoE, particularly as PPI-REE may change over time; there has been one report of four children who developed EoE aft er initially having a PPI response ( 34 ) .
We have previously reported that EoE and GERD could be distinguished using a multivariable analysis of clinical, endoscopic and histological features ( 35 ) . Th e contrast between those results and the present study, where EoE and PPI-REE could not be similarly diff erentiated, is notable. We believe that this is explained by diff erences in the comparator groups (GERD vs. PPI-REE).
the setting of an active food impaction ( 19, 20 ) . However, these studies were conducted before the recognition of PPI-REE, and not all subjects diagnosed with EoE had a previous PPI trial. Th erefore, these estimates almost certainly include a mix of both EoE and PPI-REE patients. Th e prevalence of EoE in patients undergoing endoscopy for dysphagia in our study is higher than previously reported and may refl ect continuing trends in the increasing incidence of EoE ( 21 ), referral bias from procedures performed at an academic center, selection bias given that less than half of patients screened were enrolled, or a combination of all three. However, even if we assume that all of the subjects who were screen failures had normal esophageal biopsies, esophageal eosinophilia and EoE would still be quite common in the dysphagia population.
Interestingly, our estimate of the prevalence of the proportion of patients with esophageal eosinophilia who responded to a PPI trial is very similar to other estimates of PPI-REE in the literature ( Table 3 ) ( 10 -15,22 -26 ) . Th e majority of studies on PPI-REE have been retrospective and report that 39 -71 % of children and adults with esophageal eosinophilia have PPI-REE. In the fi rst prospective study examining PPI-REE, MolinaInfante et al. ( 12 ) enrolled 712 adults in Spain undergoing upper endoscopy for any indication, and 35 (4.9 % ) had ≥ 15 eos / hpf on esophageal biopsy. Subjects were treated with rabeprazole 20 mg twice daily for 2 months and then underwent upper endoscopy. A total of 26 (74 % ) had resolution of esophageal eosinophilia and were classifi ed as PPI-REE. Both in this study, and in the one by Francis et al. ( 14 ) where the frequency of PPI-REE was 61 % , baseline refl ux testing was not predictive of PPI-REE status ( 12, 14 ) . Other prospective studies in which information can indirectly be inferred about PPI-REE prevalence are two clinical trials of fl uticasone vs. esomeprazole for patients with esophageal 
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In the fi rst study, GERD patients had to have at least one typical symptom of GERD (i.e., heartburn, regurgitation, etc) which was the main indication for esophagogastroduodenoscopy, consistent biopsy fi ndings (infl ammation which could, but did not have to, contain eosinophils), and a clinical evaluation which excluded other possible causes. Th ere were no restrictions on esophageal eosinophil counts in the GERD patients, but while some in this group had eosinophil-predominant infl ammation, many had mixed infl ammatory infi ltrates that would not be consistent with EoE and therefore would not be eligible for the present study. In contrast, in the present study, all patients started with a purely eosinophilic infi ltrate and a clinical picture that was suspicious for EoE. Subjects with GERD-predominant symptoms and with eosinophils and a mixed infl ammatory infi ltrate would not have been included in the esophageal eosinophilia group. Th erefore, the conclusions of the studies are diff erent -predictors do exist to separate EoE from GERD patients but not EoE from PPI-REE patients.
Th is study has limitations that should be considered in interpreting the results. First, it was performed in an academic referral center, so the prevalences may not be generalizable to other practice settings. However, the features of subjects with esophageal eosinophilia, EoE, and PPI-REE are similar to those previously reported and the prevalence of PPI-REE is in the same range as other studies. Second, not every subject can be recruited in a PPInaive state, so some EoE patients had their index endoscopy on PPI. Although this limits the sample size for baseline PPI-naive comparisons, a post-hoc sensitivity analysis showed that there were no signifi cant diff erences between EoE patients who had a PPInaive baseline endoscopy and those who did not. Furthermore, our population is similar to that which might be encountered by the practicing clinician, given the ubiquity of PPI use. Th ird, patients found not to have esophageal eosinophilia could be on a PPI at the time of their index endoscopy. It is theoretically possible that a proportion of these patients could have had unknown esophageal eosinophilia and were then misclassifi ed as normal when they actually had PPI-REE. However, this is likely pertinent only for a small number, and if misclassifi cation were present, it would bias the diff erences noted between the study groups towards the null and underestimate the prevalence of PPI-REE. Misclassifi cation could also be possible and would also bias the results towards the null, if many of the subjects had borderline post-PPI eosinophil counts that were close to the 15 eos / hpf cutoff . For instance, three EoE subjects had eosinophil counts of 16 eos / hpf and would have been reclassifi ed with just two cells fewer. Fourth, while a symptom response was included in the defi nition of PPI-REE, given that there were no validated symptom measures in EoE available when this study was designed, we relied on patient self-report and treated it as a yes / no variable. Finally, given the size and structure of our trial, pH testing was not part of the study design. However, refl ux testing has since been shown not to predict PPI-REE status ( 12, 14 ) , and subjects in clinical practice are classifi ed by PPI administration not pH test results.
Th is study has multiple strengths. Th is is the fi rst prospective trial in the United States to explicitly assess the prevalences of EoE and PPI-REE using a clinical PPI trial, as recommended by the current guidelines for the diagnosis of EoE ( 1, 2 ) . It is also among the largest cohorts of incident esophageal eosinophilia and PPI-REE reported in the literature. Because the study was prospective, it also allowed for careful exclusion of other competing causes of esophageal eosinophilia, and in fact two cases of eosinophilic gastroenteritis overlapping with EoE were discovered due to systematic gastric and duodenal research protocol biopsies that were performed. Follow-up was compulsive, with only a single patient lost to follow-up.
In conclusion, we found that esophageal eosinophilia is common among patients undergoing upper endoscopy and that aft er a PPI trial nearly a quarter of patients with dysphagia had EoE, and PPI-REE was almost as common, accounting for over one-third of those with ≥ 15 eos / hpf. Clinical, endoscopic, and histological features could not distinguish the two groups at baseline before the PPI trial. Th is implies that novel methods are needed to distinguish these populations, with the ultimate goal of eliminating the requirement for a PPI trial from the diagnostic algorithm for EoE. However, given the current state of knowledge, these fi ndings emphasize the necessity of a PPI trial as per the current guidelines to accurately diagnose EoE. Th is is not only important clinically for patient care, but also crucial in research studies of epidemiology and treatment outcomes of patients with EoE to ensure interpretable results are generated from the homogenous patient groups. Because there could be conceptual concerns with requiring a response to a pharmacological agent in a disease defi nition, future investigations, potentially with molecular diagnostic methods, will be needed to clarify whether some patients with PPI-REE are a sub-phenotype of EoE and whether EoE could eventually be diagnosed without a PPI trial.
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